ProKidney Corp.

$0.84
(as of Jun 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for ProKidney Corp.

Stock Price
$0.84
Ticker Symbol
PROK
Exchange
NASDAQ

Industry Information for ProKidney Corp.

Sector
Healthcare
Industry
Biotechnology

Company Description for ProKidney Corp.

Website
https://prokidney.com
Country
USA
Full Time Employees
204

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Fundamentals for ProKidney Corp.

Market Capitalization
$1,811,826,048
EBITDA
$-173,734,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.59
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
129,536,000
Percent Owned by Insiders
30.05%
Percent Owned by Institutions
41.88%
52-Week High
52-Week Low

Technical Indicators for ProKidney Corp.

50-Day Moving Average
200-Day Moving Average
RSI
50.39
ATR
0.09

Analyst Ratings for ProKidney Corp.

Strong Buy
4
Buy
0
Hold
3
Sell
0
Strong Sell
0

News About ProKidney Corp.

May 12, 2025, 4:15 PM EST
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in mid-2025 after our planned Type B meeting with the FDAEnded the first quarter with $328.5 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 See more.
May 12, 2025, 4:15 PM EST
ProKidney See more.
Mar 27, 2025, 12:01 PM EST
There's no doubt that money can be made by owning shares of unprofitable businesses. See more.
Mar 21, 2025, 9:55 AM EST
ProKidney Corp. See more.